Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence - Takeaways - MDSpire

Fibroblast growth factor 23 and outcomes of atrial fibrillation: from clinical association to genetic evidence

  • By

  • Jiaju Li

  • Yiwei Lai

  • Chao Jiang

  • Mingxiao Li

  • Zejun Yang

  • Manlin Zhao

  • Xiaodong Peng

  • Sitong Li

  • Qifan Li

  • Jiawei Chen

  • Zhen Wang

  • Suhui Zhang

  • Changsheng Ma

  • Jianzeng Dong

  • January 29, 2025

  • 0 min

Share

  • 1

    Elevated serum FGF23 levels are significantly associated with increased risks of all-cause mortality, cardiovascular mortality, and heart failure in AF patients.

  • 2

    A polygenic score for FGF23 indicates a paradoxical relationship, showing reduced heart failure risk but increased all-cause mortality and ischaemic stroke risk.

  • 3

    The study analyzed data from 35,197 AF patients, providing insights into the prognostic value of FGF23 in atrial fibrillation outcomes.

  • 4

    FGF23 may serve as a potential biomarker for assessing AF-related outcomes, highlighting its clinical implications for AF management.

  • 5

    Further investigation is needed to understand the underlying mechanisms of the paradoxical associations between genetic and serum FGF23 levels.

Original Source(s)

Related Content